General Information of Drug (ID: DMH4IVU)

Drug Name
Haloprogin Drug Info
Synonyms
Aloprogen; Haloprogina; Haloprogine; Haloproginum; Halotex; Mycanden; Mycilan; Polik; Component of Halotex; M 1028; Haloprogina [INN-Spanish]; Haloprogine [INN-French]; Haloproginum [INN-Latin]; Halotex (TN); Mycanden (TN); Mycilan (TN); Polik (TN); Haloprogin [USAN:INN:JAN]; M-1028 (Meiji); Haloprogin (JAN/USAN/INN); Ether, 3-iodo-2-propynyl 2,4,5-trichlorophenyl; Benzene,1,2,4-trichloro-5-[(3-iodo-2-propynyl)oxy]; (3-Iod-2-propinyl)-(2,4,5-trichlorphenyl)ether; 1,2,4-trichloro-5-(3-iodoprop-2-ynoxy)benzene; 1,2,4-trichloro-5-[(3-iodo-2-propynyl) oxy]benzene; 2,4,5-Trichlorophenyl .gamma.-iodopropargil ether; 2,4,5-Trichlorophenyl .gamma.-iodopropargyl ether; 2,4,5-Trichlorophenyl gamma-iodopropargil ether; 2,4,5-Trichlorophenyl iodopropargyl ether; 2,4,5-Trichlorophenyl-gamma-iodopropargyl ether; 3-Iodo-2-propynyl 2,4,5-trichlorophenyl ether
Indication
Disease Entry ICD 11 Status REF
Candidiasis 1F23 Approved [1]
Dermatophytosis 1F28.2 Approved [1]
Tinea corporis 1F28.Y Approved [2]
Tinea cruris 1F28.3 Approved [2]
Tinea pedis 1F28.2 Investigative [2]
Therapeutic Class
Antifungal Agents
Cross-matching ID
PubChem CID
3561
ChEBI ID
CHEBI:5614
CAS Number
CAS 777-11-7
TTD Drug ID
DMH4IVU

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Natamycin DMFEHXD Conjunctivitis 9A60 Approved [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fungal Cell membrane (Fung CM) TTAH0B3 NOUNIPROTAC Binder [3]

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Haloprogin FDA Label
3 Haloprogin: mode of action studies in Candida albicans. Can J Microbiol. 1974 Sep;20(9):1241-5.
4 Natamycin blocks fungal growth by binding specifically to ergosterol without permeabilizing the membrane. J Biol Chem. 2008 Mar 7;283(10):6393-401.